Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Fibrocor Therapeutics","sponsor":"McQuade Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Fibrocor Therapeutics Enters into Research and Development Collaboration with McQuade Center for Strategic Research and Development to Advance Alport Syndrome Program","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling"}]

    Find Clinical Drug Pipeline Developments & Deals by Fibrocor Therapeutics

    Menu

    Fibrocor Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Fibrocor Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Fibrocor Therapeutics Enters into Research and Development Collaboration with McQuade Center for Strategic Research and Development to Advance Alport Syndrome Program

              Details:

              The collaboration aims to support the clinical development of Fibrocor's FIB918, a monoclonal antibody. Currently, it is being evaluated in the IND-enabling phase for the treatment of Alport Syndrome.

              Lead Product(s): FIB918

              Therapeutic Area: Genetic Disease Product Name: FIB918

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: McQuade Center

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration March 05, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY